Chorioallantoic membrane tumor models highlight the effects of cisplatin compounds in oral carcinoma treatment.
Biological sciences
Cancer
Molecular biology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
18 Mar 2022
18 Mar 2022
Historique:
received:
30
11
2021
revised:
31
01
2022
accepted:
19
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
The European Society for Medical Oncology (ESMO) suggests the use of chemotherapy as neoadjuvant, adjuvant, and concomitant to surgery and radiotherapy for the treatment of oral carcinoma by depending on the cancer stage. The usual drug of choice belongs to the platinum compounds. In this context, the evaluation of the cancer behavior associated with the administration of standard or emerging cisplatin compounds supports the establishment of optimal cancer management. Here, we have assessed and compared the performance of cisplatin alone and contained in biodegradable nanocapsules on standardized chorioallantoic membrane (CAM) tumor models. The vascularized environment and optimized grafting procedure allowed the establishment of solid tumors. The treatments showed antitumor and anti-angiogenic activities together with deregulation of pivotal genes responsible of treatment resistance and tumor aggressiveness. This study further supports the significance of CAM tumor models in oncological research for the comprehension of the molecular mechanisms involved in tumor treatment response.
Identifiants
pubmed: 35310338
doi: 10.1016/j.isci.2022.103980
pii: S2589-0042(22)00250-4
pmc: PMC8924639
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103980Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
J Cell Biochem. 2008 Dec 1;105(5):1202-10
pubmed: 18802921
Diagnostics (Basel). 2020 Dec 27;11(1):
pubmed: 33375464
Sci Rep. 2017 Mar 17;7:44686
pubmed: 28304379
Clin Cancer Res. 2005 May 1;11(9):3530-4
pubmed: 15867256
Br J Pharmacol. 2013 Oct;170(4):712-29
pubmed: 23962094
Technol Cancer Res Treat. 2016 Feb;15(1):139-45
pubmed: 25731804
Neoplasia. 2015 Feb;17(2):190-200
pubmed: 25748238
Methods Mol Biol. 2015;1207:305-15
pubmed: 25253149
ACS Appl Bio Mater. 2019 Oct 21;2(10):4464-4470
pubmed: 35021406
Sci Rep. 2017 Mar 03;7:43795
pubmed: 28256565
J Clin Diagn Res. 2015 Oct;9(10):XC08-XC12
pubmed: 26557601
Drug Saf. 2015 Feb;38(2):129-52
pubmed: 25577497
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Angew Chem Int Ed Engl. 2014 Nov 10;53(46):12320-64
pubmed: 25294565
Front Oncol. 2016 Mar 29;6:69
pubmed: 27066453
Int J Cancer. 2010 Jan 1;126(1):65-72
pubmed: 19536778
Head Neck. 2008 Sep;30(9):1216-23
pubmed: 18642295
Cancer Med. 2017 Jan;6(1):288-297
pubmed: 28028936
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6700-5
pubmed: 23569259
Eur Arch Otorhinolaryngol. 2011 May;268(5):661-70
pubmed: 21246209
Expert Opin Drug Metab Toxicol. 2021 Aug;17(8):947-968
pubmed: 33565346
Int J Mol Sci. 2019 Oct 08;20(19):
pubmed: 31597249
ACS Omega. 2018 Sep 30;3(9):11796-11801
pubmed: 30320273
Int J Biol Sci. 2009 Jun 28;5(5):466-73
pubmed: 19584954
Methods Enzymol. 2008;444:21-41
pubmed: 19007659
Handb Exp Pharmacol. 2021;265:303-323
pubmed: 32776283
Br J Cancer. 2000 Sep;83(6):775-81
pubmed: 10952783
Front Bioeng Biotechnol. 2018 Oct 08;6:143
pubmed: 30349817
Oral Oncol. 2009 Apr-May;45(4-5):324-34
pubmed: 18805044
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Biol Pharm Bull. 2013;36(3):370-5
pubmed: 23268881
Int J Mol Sci. 2018 Feb 02;19(2):
pubmed: 29393886
PLoS One. 2019 Apr 15;14(4):e0215312
pubmed: 30986223
Cancers (Basel). 2020 Apr 25;12(5):
pubmed: 32344838
Enzymes. 2019;46:129-160
pubmed: 31727274
Cancer. 2016 Dec 1;122(23):3592-3595
pubmed: 27649273
Chem Commun (Camb). 2015 Jun 21;51(49):9939-41
pubmed: 25998799
Br J Pharmacol. 2016 Sep;173(17):2633-44
pubmed: 27351124
J Cell Mol Med. 2006 Jul-Sep;10(3):588-612
pubmed: 16989723
Am J Clin Oncol. 2014 Apr;37(2):154-61
pubmed: 23211218
ACS Pharmacol Transl Sci. 2021 Apr 14;4(3):1227-1234
pubmed: 34151212
Bioconjug Chem. 2018 Jan 17;29(1):4-16
pubmed: 29186662
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
Radiother Oncol. 2018 Apr;127(1):20-26
pubmed: 29534828
Eur J Cancer. 1995;31A(5):819-22
pubmed: 7640066
Nanomaterials (Basel). 2020 Aug 14;10(8):
pubmed: 32824106
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415
N Engl J Med. 2008 Sep 11;359(11):1143-54
pubmed: 18784104
Semin Oncol. 2014 Apr;41(2):217-34
pubmed: 24787294
Nanoscale Adv. 2020 Jul 22;2(9):3815-3820
pubmed: 36132776
Acta Oncol. 1988;27(2):131-46
pubmed: 3390344
Curr Treat Options Oncol. 2019 Apr 22;20(5):43
pubmed: 31011837
Nat Rev Cancer. 2005 Jul;5(7):516-25
pubmed: 15965493
Cancer Biother Radiopharm. 2016 Sep;31(7):233-7
pubmed: 27610466
Head Neck Oncol. 2009 Mar 02;1:6
pubmed: 19284526
PLoS One. 2014 Jul 23;9(7):e101638
pubmed: 25054864
Oral Oncol. 2015 May;51(5):409-15
pubmed: 25680863
Genes Cancer. 2011 Dec;2(12):1117-33
pubmed: 22866203
Int J Surg Pathol. 2014 Feb;22(1):12-32
pubmed: 24406626
Int J Mol Sci. 2014 Oct 23;15(10):19265-80
pubmed: 25342321
J Colloid Interface Sci. 2021 Jan 15;582(Pt B):1003-1011
pubmed: 32927167
Eur Arch Otorhinolaryngol. 2014 Aug;271(8):2253-9
pubmed: 24121822